Wells Fargo
QTTB icon

Wells Fargo’s Q32 Bio QTTB Stock Holding History

Wells Fargo’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-222
Closed -$12K – 7634
2022
Q1 		$12K Buy
+222
New +$13.8K ﹤0.01% 6218

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's QTTB Position: Q1 2026 in Review

Wells Fargo opened a new position in Q32 Bio (QTTB) in Q1 2026: 84 shares worth $539. The stake represents ﹤0.01% of the portfolio and ranks #6391 among its holdings. This is a return to the name: Wells Fargo previously reported a position in QTTB as recently as Q2 2025.

Wells Fargo first reported a position in QTTB in Q2 2018 and has held it in 30 quarters since. The position peaked at $542K in Q4 2019. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Wells Fargo held 84 shares of Q32 Bio worth $539 as of Q1 2026.
  • Q32 Bio was a new Wells Fargo position in Q1 2026.
  • Q32 Bio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6391 holding.
  • Wells Fargo first reported a position in Q32 Bio in Q2 2018 and has held it in 30 quarters since.
  • Wells Fargo's Q32 Bio position peaked at $542K in Q4 2019.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.